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 Introduction 
 Many studies have examined the role of the apolipo-
protein E (ApoE) genotype associated with the risk of de-
veloping Alzheimer’s disease (AD). Approximately 78% 
of the population possesses the   3 allele making it the 
most commonly expressed. The   4 allele is found in 22% 
of the US and European populations, and the   2 allele in 
only 7%  [1] . The   4 allele has been associated with an in-
creased risk of AD  [2] and is widely considered a signifi-
cant contributor to the pathogenesis of AD. Additionally, 
the   4 allele has been linked to individuals with vascular 
disease. Of the 6 possible genotypes,   2/  2 is the rarest 
and is present in less than 1.4% of the general population. 
 The   2 allele has been suggested to have the protective 
effect of delaying age of onset of AD  [3] . Dementia sub-
jects with the ApoE   22 allele have reduced   -amyloid 
pathology in the frontal and parietal cortices compared 
to patients with AD with the   3/  3 genotype  [4] . In a re-
cent case report, an   2 homozygote was described as hav-
ing minimal cognitive decline (MMSE 28/30 proximate 
to death) despite significant plaque and tangle burden 
found on autopsy, suggesting that ApoE   22 might pro-
tect against cognitive decline, even in the presence of sig-
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 Abstract 
 Objective: To describe a case of early-onset Alzheimer’s dis-
ease (AD) in an apolipoprotein (Apo)   2/  2 homozygote. 
 Background: Apo   2/  2 is the rarest of the ApoE genotypes, 
representing only 1.4% of the population. Cognitive decline 
in ApoE   2 homozygotes has rarely been reported.  Case Re-
port/Methods: We report a 58-year-old Apo   2/  2 female 
who meets clinical criteria for probable AD as confirmed by 
neuropsychological testing, positron emission/computed 
tomography scan, CSF analysis and genetic screening for 
known mutations.  Results: The clinical course is typical of 
AD, with progressive cognitive and functional decline.  Con-
clusion: Clinically confirmed early-onset AD is atypical in 
ApoE2 homozygotes but can occur. 
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nificant neuropathology  [5] . Previously, we reported the 
first case of an ApoE   2/  2 carrier with clinically con-
firmed AD  [6] . Here, we describe a second case involving 
an   2 homozygote with clinically confirmed AD but with 
presenile onset.
 Case Report 
 The subject is a 58-year-old left-handed Caucasian female with 
12 years of education. Memory loss was noted by a friend of 40 
years who described significant personality and cognitive chang-
es following an appendectomy in the summer of 2006. At the time 
she presented to our clinic, she was reported to have had a change 
in personality characterized by decreased anger and irritability in 
addition to an impaired sense of direction with a tendency to get 
lost. Professionally, she had experienced troubles over the previ-
ous few years which ultimately led to her retirement. She exhib-
ited name-finding and word-finding difficulty. No hallucinations 
or delusions were reported. 
 The patient’s medical history at the initial presentation includ-
ed hypothyroidism, hypercholesterolemia, foot surgery, mastec-
tomy and appendectomy. Her medications at the initial presenta-
tion included simvastatin, levothyroxine and aspirin. Her family 
history was unremarkable for degenerative brain conditions; it 
was specifically unremarkable for AD or frontotemporal demen-
tia (FTD). She was reported to be a social drinker but may have 
been drinking more in the past although there was not a reliable 
quantification available. At the time of evaluation, she was not 
reported to be consuming alcohol. She did not smoke or use illegal 
drugs. Review of systems established a tendency to binge and 
purge. There was no bladder or bowel incontinence reported. 
 Physical examination at the initial evaluation was significant 
for normal vital signs including normotensive blood pressure and 
normal cardiac, carotid, pulmonary, abdominal and extremity 
examinations. 
 Cognitive screening at the initial evaluation showed alert 
mentation with fluent speech. The patient was able to repeat, 
name and follow commands. She demonstrated a Functional As-
sessment Staging score of 3  [7] . Her MMSE score was 23 out of 30 
with points lost for repetition, 3-step command, praxis, naming 
and recall  [8] . Normal clock drawing and intact generative speech 
were demonstrated. Registration for a name and address was 5/5, 
and 5-min recall was 4/5. Her neurological examination revealed 
intact cranial nerves. Motor examination confirmed normal tone, 
intact and symmetric strength in all extremities and absence of 
muscular atrophy. Deep tendon reflexes were 2+ at the biceps, tri-
ceps, brachioradialis and patella. Sensation to light touch, pin-
prick, vibration and proprioception was preserved. Coordination 
showed apraxia for finger-nose-finger and rapid alternating 
movements. Gait showed normal base and stance, with normal 
toe, heel and tandem walking. 
 The initial diagnostic impression was FTD mainly given the 
presenile onset and the presence of some personality change. Giv-
en her younger age, a complete evaluation including neuropsy-
chological assessment, positron emission tomography scan with 
computed tomography (PET-CT) and CSF testing were under-
taken.
 Neuropsychological testing ( tables 1–4 ) included Testing of 
Memory Malingering  [9] , Wechsler Abbreviated Scale of Intelli-
gence  [10] , Repeatable Battery for the Assessment of Neuropsy-
chological Status (RBANS A)  [11] , Trail-Making Tests A and B 
 [12] , Wechsler Adult Intelligence Scale, third edition (digit span) 
 [13] , Token Test  [14, 15] , Controlled Oral Word Association Test 
 [16] , Animal Fluency Test, Boston Naming Test  [17] , Judgment of 
Line Orientation  [18] , Stroop Test  [19, 20] , Test of Facial Recogni-
tion  [21] , 6-Item Cognitive Impairment Test  [22] and the Clock-
Drawing Task  [23, 24] .
 The patient demonstrated impairment across measures with 
the exception of confrontation naming Boston Naming Test and 
attention (digit span). RBANS list learning was moderately im-
paired across 4 trials. List recall was mildly impaired with 2/10 
words produced. Recognition memory was moderately impaired 
with 17 hits and 3 false-positive errors. RBANS immediate narra-
tive recall was severely impaired (6/12 details recalled across 2 
trials). Delayed narrative recall remained moderately impaired 
with 4/6 details recalled. She recalled 3 of 20 RBANS complex fig-
ure details after a delay (severe impairment). Language measures 
were moderately (animal fluency) to severely impaired (Con-
trolled Oral Word Association Test, Token Test). Aspects of her 
Table 1. T est of Memory Malingering (TOMM), Blessed Orienta-
tion, Memory and Concentration Test (OMCT) and Clock-Draw-
ing Test results
TOMM T1 raw = 44
TOMM T2 raw = 46
Blessed OMCT raw = 14
Clock-Drawing Test raw = 6/10
Table 2. R epeatable Battery for the Assessment of Neuropsycho-
logical Status A results
Immediate memory 0.1 percentile
Visuospatial <0.1 percentile
Language 8th percentile
Attention 0.2 percentile
Delayed memory 0.2 percentile
List learning raw = 17 z = –2.23
Story memory raw = 6 z = –3.11
Figure copy raw = 11 z = –5.11
Line orientation raw = 2 z = –4.97
Picture naming raw = 10 z = +0.67
Semantic fluency raw = 11 z = –2.00
Digit span raw = 8 z = –1.04
Coding raw = 3 z = –4.87
List recall raw = 2 z = –1.90
List recognition raw = 17 z = –2.50
Story recall raw = 4 z = –2.32
Figure recall raw = 3 z = –3.81
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token performance were believed to be due to ideomotor apraxia 
impairment. Visuospatial processing skills were moderately (fa-
cial recognition) to severely impaired (RBANS Judgment of Line 
Orientation and figure copy, Benton Judgment of Line Orienta-
tion). Processing speed was significantly reduced (Stroop word 
reading/color naming, Trail-Making Test A, RBANS coding). Ex-
ecutive functions were severely impaired (Trail-Making Test B, 
Stroop interference). The preponderance of frontal, visuospatial 
and language deficits noted were equal to or greater than memo-
ry impairments, which raised the question of a possible FTD. 
However, memory deficits were apparent and demonstrable with 
early onset and rapid progression. A possible AD variant with 
greater visuospatial and frontal involvement was hypothesized.
 A PET scan with CT fusion of the brain showed mild symmet-
ric cerebral atrophy without focality. Her ventricles and sulci were 
prominent for age. There were no masses, hemorrhages, white 
matter rarefaction, midline shift or CT evidence of acute infarcts 
detected. Marked hypometabolism associated with the frontal, 
temporal and parietal lobes was observed as well as hypometabo-
lism of the posterior cingulate gyrus. The motor cortex, basal nu-
clei, occipital lobes and cerebellum appeared to be spared of the 
hypometabolism. These findings are consistent with advanced 
AD and not consistent with FTD. There were no masses, hemor-
rhages, midline shift or CT evidence of acute infarcts. 
 ApoE genotyping was performed by restriction endonuclease 
digestion of PCR-amplified genomic DNA by Athena Diagnostics. 
The patient did not possess an ApoE   4 allele. The result – ApoE 
genotype: 2 and 2. This analysis performed at Athena Diagnostics 
is greater than 99% accurate. Analysis of the patient’s profile did 
not identify abnormal DNA sequence variants in the coding re-
gion and intron/exon junctions for the  PSEN1, PSEN2 and  APP 
genes. Furthermore, no duplication of the  APP gene was detected. 
Forwards total/span = 11/7 +0.45
Backwards total/span = 3/3 z = –0.99
Total raw = 14 ScS = 9
Token raw = 23 severe impairment
COWAT (CFL) raw = 8 ScS ≤ 2
Animal fluency raw = 10 z = –2.06
Boston Naming Test raw = 56 ScS = 10
JLO raw = unable to acquire task
Facial recognition raw = 37 converted long moderate impairment
Trials A 222; 0 error ScS ≤ 2
Trials B unable to do impaired
COWAT = Controlled Oral Word Association Test; ScS = scaled score; JLO = Judg-
ment of Line Orientation Test.
Table 4.  Stroop results
W – 53 ScS ≤ 2
C – 20 ScS ≤ 2
CW – 5 ScS ≤≤ 2
ScS = Scaled score.
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 Fig. 1.  a Axial PET showing hypometabo-
lism of parietal and posterior cingulate 
 gyrus.  b Axial CT showing no significant 
ischemic changes and no regional/focal at-
rophy. 
Table 3.  Digit span results
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 CSF testing for 42-amino-acid   -amyloid (A  42), tau and 
phosphorylated (phospho) tau was done by Athena Diagnostics. 
Determination of A  (1–42) peptide, total tau and phospho-tau 
concentrations in CSF was performed by ELISA methodology as 
provided by Innogenetics NV [Innotest TM   -Amyloid(1–42), In-
notest hTAU Ag and Innotest Phospho-tau]. Concentrations were 
determined from standard curves using synthetic A  (1–42) pep-
tide, recombinant human total tau protein and a synthetic 
34-amino-acid peptide phosphorylated at the position equivalent 
to threonine-181 in the tau protein. An A  (1–42) tau index was 
calculated as ATI = [A  (1–42)]/(240 + 1.18 total tau) and repre-
sents a ratio normalized by the discrimination line A  (1–42) = 
240 + 1.18 total tau. This line represents a sensitivity of 85–94% 
and specificity of 83–89% for distinguishing AD from non-AD 
populations with an ATI value of 1.0 being on the line. An ATI of 
less than 1.0 typically designates individuals with AD as com-
pared to an ATI of greater than 1.0, found to correlate with non-
AD individuals. The phospho-tau level provides an analytical tool 
for differentiating AD from other forms of dementia. A phospho-
tau  1 61 pg/ml typically distinguishes AD from FTD and demen-
tia with Lewy bodies as indicated by phospho-tau levels  ! 61 pg/
ml with sensitivities of 72–85% and specificities of 74–85%. Con-
sistent with a diagnosis of AD, the patient possessed reduced lev-
els of cerebrospinal A  (1–42) of 288.75 pg/ml, a total tau of 
1,082.05 pg/ml and an elevated phospho-tau protein concentra-
tion of 123.5 pg/ml. These levels resulted in an ATI of 0.19.
 The patient returned for follow-up 9 months later. Her MMSE 
had declined to 18/30 despite treatment with a cholinesterase in-
hibitor and memantine. She continued to live alone but financial 
matters were handled by power of attorney. 
 Discussion 
 This is the second reported case of a clinically con-
firmed patient with probable AD with an ApoE   2/  2 ho-
mozygote. Clinical findings of dementia are supported by 
neuropsychological testing, PET/CT scan and CSF. While 
the presenile onset for this patient favors the diagnosis of 
FTD, the CSF markers, specifically the ATI as well as the 
PET scan favor a diagnosis of AD.
 As determined by the total tau concentration and re-
duced CSF levels of A  (1–42) peptide, an ATI of less than 
1.0 typically indicates a diagnosis of AD while a value 
 1 1.0 is typical of control populations representing nor-
mal aging, alcohol dementia, depression, psychological 
and other neurological disorders. A phospho-tau level of 
 1 61 pg/ml has been found to discriminate AD from FTD 
and dementia with Lewy bodies with sensitivities rang-
ing from 72–85% and specificities of 74–85%  [25, 26] . 
Most studies have found normal to mildly increased CSF 
total tau levels in other dementias such as FTD and de-
mentia with Lewy bodies  [27] . 
 It is possible that the PET/CT and CSF markers give 
false-positive results. However, Silverman et al.  [28] re-
ported a 93% positive predictive value with PET for AD. 
Further CSF testing for A  42/tau in AD is 89% sensitive 
and 90.2% specific  [27] .
 It has been speculated that the   2 allele is protective in 
AD. In fact, not only is there evidence of delay of disease 
onset  [3] , but there appears to be reduced frequency of 
sporadic cases with ApoE   2/  2. In view of the presenile 
onset of AD experienced by this patient, this case direct-
ly challenges the concept that the   2 allele has a protective 
effect against early-onset AD. To our knowledge, there 
has not been a report of an   2 homozygote with patho-
logically confirmed AD. Prior to our report, Berlau et al. 
 [5] had a case report of an ApoE   2/  2 subject with ad-
vanced age who showed minimal cognitive changes prior 
to death, but significant neuropathological changes on 
postmortem examination consistent with AD. In fact, a 
presenile onset would typically favor an ApoE   4 homo-
zygote or an autosomal dominant form of AD.
 The interaction between ApoE and neuropathological 
changes has been investigated extensively. Many have 
found that the presence of ApoE   4 is associated with an 
increased burden of pathological change associated with 
AD  [29] . Alternative mechanisms for interaction between 
ApoE and neuropathological changes have been explored 
 [30, 31] .
 This case has not yet gone to autopsy to confirm diag-
nosis. Consequently, the presence of AD pathology is un-
known  [32] . It is possible that the subject has the Testing 
of Memory Malingering 40 Poly T repeat  [33] but this was 
not assessed as the test is not commercially available. Giv-
en the combined results of the neuropsychological test-
ing, the ATI, phospho-tau concentration and corrobora-
tive PET/CT scan, a diagnosis of AD seems likely  [28] .
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